Drugs.com - New Drug Approvals

FDA Approves Lilly's Omvoh (mirikizumab-mrkz) for Crohn's Disease, Expanding Its Use to the Second Major Type of Inflammatory Bowel Disease

INDIANAPOLIS, Jan. 15, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Omvoh (mirikizumab-mrkz) for the treatment of moderately to severely active Crohn's disease...

Feb 9, 2025 - 22:25
 0
FDA Approves Lilly's Omvoh (mirikizumab-mrkz) for Crohn's Disease, Expanding Its Use to the Second Major Type of Inflammatory Bowel Disease
INDIANAPOLIS, Jan. 15, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Omvoh (mirikizumab-mrkz) for the treatment of moderately to severely active Crohn's disease...
Read More

Tags:

Previous Article

FDA Approves Lumakras (sotorasib) in Combination with Vectibix (panitumumab) for...

Next Article

Incyte and Syndax Announce U.S. Food and Drug Administration (FDA) Approval of N...

Related Posts

U.S. FDA Grants Full Approval of Vitrakvi (larotrectinib) for Adult and Pediatric Patients with NTRK Gene Fusion-Positive Solid Tumors

U.S. FDA Grants Full Approval of Vitrakvi (larotrectini...

Apr 14, 2025  0

FDA Grants Accelerated Approval for Vanrafia (atrasentan) for Proteinuria Reduction in Primary IgA Nephropathy

FDA Grants Accelerated Approval for Vanrafia (atrasenta...

Apr 4, 2025  0

U.S. FDA Approves Expanded Label for Astellas' Izervay (avacincaptad pegol intravitreal solution) for Geographic Atrophy

U.S. FDA Approves Expanded Label for Astellas' Izervay ...

Feb 13, 2025  0